Dr Glenn A Harris

Dr Glenn A Harris

Glenn A Harris, PhD, is an established contributor across the drug development ecosystem for the Rainwater Charitable Foundation, driving efforts to advance promising targets from discovery to the clinical trial phase. He is notably involved in initiatives related to neurodegenerative disorders, where he emphasises the critical need for well-defined targets, drugs and biomarkers to accelerate therapeutic breakthroughs. Dr Harris has authored numerous publications detailing the therapeutic landscape and novel methods for molecular analysis in drug and biomarker development.

  • Tau,Tangles,And,Amyloid,Beta,Concept,As,Abnormal,Clusters,Of
    Article

    Why tau still lacks treatments and how funders are responding

    2026-01-13T08:30:00

    Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.